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To the Editor,
Treatment with ponatinib may induce arterial occlusive
events (AOEs) that can limit its effectiveness, suggesting
caution in its use in patients with pre-existing cardio-
vascular (CV) risk factors or CV disease. Variable rates of
AOEs have been reported in both randomized clinical
trials and in real-life studies1–3. Several risk factors asso-
ciated with the development of AOEs have been sug-
gested4. In addition, the Systematic Coronary Risk
Evaluation (SCORE) scoring system based on sex, age,
systolic pressure, smoking and total cholesterol level has
been proposed to predict the risk of fatal CV disease over
a 10 years period5,6. Dyslipidemia is considered a major
risk factor for CV disease. New evidences have shown that
the atherosclerotic plaque formation is initiated by the
accumulation in the arterial wall of low-density lipopro-
teins (LDL), cholesterol and other cholesterol-rich apoli-
poprotein (Apo) B-containing lipoproteins7. Very
recently, the European Society of Cardiology (ESC) and
the European Atherosclerosis Society (EAS) have pub-
lished new guidelines for the management of dyslipidemia
and lipid modification in order to reduce the risk of CV
events8. So far, no data on the management of dyslipi-
demia in CML patients treated with ponatinib have been
reported. We therefore analyzed a large real-life cohort of
Italian patients with CML treated with ponatinib outside
of clinical trials and evaluated the role of dyslipidemia.
The primary endpoint was to establish the association
between AOEs and plasma lipoproteins levels; moreover,
we estimated the prognostic value of the new SCORE
chart to predict AOEs.
A large series of 116 adult CML patients treated with
ponatinib in the real life between January 2012 and
December 2019 in 20 Italian centers, was investigated.
The study was conducted in accordance with the
Declaration of Helsinki.
The concentration of plasma cholesterol, HDL, LDL,
and triglycerides at CML diagnosis was collected, before
starting the treatment with ponatinib and therefore after
3, 6, and 12 months of treatment. Normal plasma levels
where considered as following: cholesterol and triglycer-
ides <200 mg/dL, HDL > 40mg/dL, and LDL < 130mg/
dL. Two additional optimal targets of LDL values for high
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(<70 mg/dL) and very-high risk CV patients (<55 mg/dL)
were also considered in the analysis8.
We estimated the new low-risk SCORE chart for Eur-
opean populations8. The new version of the SCORE dif-
fers slightly from that of 20165, because age has been
extended and the interaction between age and the other
risk factors has been incorporated, thus reducing the
overestimation of risk in older persons. The patients were
stratified into low to moderate (SCORE ≤ 5%) or high to
very high (SCORE risk >5%) CV risk. We recorded any
cases of primary or secondary antithrombotic prophylaxis
and treatments of dyslipidemia with statins or fibrates. All
AOEs (cerebrovascular, peripheral vascular, and CV
events excluding hypertension) were collected. The
cumulative incidence of AOEs was estimated after
administering ponatinib. The log-rank test was used to
compare two or more groups of stratified patients. Mul-
tivariate analyses were performed using the Cox propor-
tional hazards regression model. A p-value < 0.05 was
considered statistically significant.
The patients’ characteristics of the 116 chronic CML
patients are shown in Table 1. The median age was 49
years (range 23–81) and the Sokal score was intermediate-
high in 76% of patients. A positive history for CV diseases
was reported in 20% of patients. The median follow-up
was 3.5 years (range 1–5). In the majority of cases (64%),
ponatinib was administered as third or subsequent lines of
treatment for inefficacy (82%) or intolerance (18%) to
other TKIs; at the start of treatment 23% of patients
harbored a T315I mutation.
At baseline, ponatinib was administered at the following
doses: 45 mg/day in 36% of patients, 30 mg/day in 48% of
patients, and 15mg/day in 16% of patients, respectively.
The median time of drug exposure was 16 months (range
1–60). In our cohort of 116 patients, 15 patients with
hypertension and 16 with AOEs were recorded (Table 1).
Among the patients with AOEs 31% had received 45mg/
day of ponatinib, 38% 30mg/day and 31% 15mg/day,
respectively. No association was found between AOEs and
dose of ponatinib or previous exposure to nilotinib. The
median time elapsed between the start of ponatinib
treatment and the onset of AOEs was 9 months (range
1–48). Overall, the 4-year cumulative incidence rate of
AOEs was 26.5 ± 7%. Following the occurrence of AOEs
and hypertension, 13 patients discontinued treatment; the
dose of ponatinib was reduced in six patients and
remained unchanged in 12. The 4-year cumulative inci-
dence rate of MR4 following ponatinib treatment was
76.7 ± 11.7%, and it was not influenced significantly by
AOE occurrence. Finally, the 4-year overall survival (OS)
was 92.2 ± 3.4%.
Median plasma values and range of cholesterol, LDL,
HDL, and triglycerides were collected at CML diagnosis,
at the start of ponatinib therapy and after 3, 6, and
12 months of treatment. Triglycerides at the start of
treatment with ponatinib, cholesterol, and LDL after
3 months of treatment were found significantly higher in
comparison with others timepoints (P= 0.007, P= 0.02,
and P= 0.002, respectively) (Supplementary Fig. 1).
Patients with cholesterol plasma levels > 200mg/dL and
LDL > 70mg/dL after 3 months of treatment with pona-
tinib, showed a significantly higher incidence of AOEs
(44.1 ± 11% vs. 7.7 ± 7.4, P= 0.001; data available on 82
patients) (Fig. 1a). The rate of AOEs was similar when
considering at 3 months patients with a LDL threshold
above 55mg/dL. Patients with triglycerides plasma levels
>200 mg/dL before starting ponatinib, showed a sig-
nificantly higher incidence of AOEs (44.6 ± 14% vs. 8.7 ±
8.8, P < 0.001; data available on 94 patients) (Fig. 1b). In
multivariate analysis, cholesterol plasma levels > 200mg/
dL and LDL > 70mg/dL after 3 months and triglycerides
plasma levels > 200 mg/dL before the start of ponatinib
maintained a significant association with AOEs (P= 0.03;
HR= 9.4; 95% CI= 1.2–72.5 and P= 0.004; HR= 7.1;
95% CI= 1.8–26, respectively).
Overall, 26 patients (22%) presented dyslipidemia at
CML diagnosis and 41 (35%) at the start of treatment with
ponatinib. Despite dyslipidemia, only 10 patients were
taking statins during the treatment with ponatinib and
only 2 started it after 3 months of ponatinib.
According to the new SCORE risk chart evaluation the
majority of the 116 patients (72%) were classified at low to
intermediate risk (SCORE risk ≤5%) and 28% of patients
at high to very high risk (SCORE risk >5%). Patients
belonging to the high and very high SCORE risk group
showed a significantly higher incidence of AOEs (46.4 ±
15.3% vs. 20 ± 7.7%, p= 0.012) (Supplementary Fig. 2). In
multivariate analysis the high–very-high SCORE risk
maintained a significant association with AOEs (p= 0.04;
HR= 2.9; 95% CI= 1–9.1).
Due to off-target effects, several adverse effects can
occur in CML patients treated with TKIs, including
endocrine and metabolic toxicity9,10. A possible role of
TKIs as modifiers of the lipoprotein profile or in the
atherogenic process has been scarcely explored. In vitro
studies have shown that ponatinib elevates the levels of
desmosterol, a substrate of 24-dehydrocholesterol reduc-
tase, the enzyme responsible for converting desmosterol
to cholesterol11. In APOE*3Leiden.CEPT transgenic mice,
a well-established model for dyslipidemia and athero-
sclerosis, it has been shown that nilotinib and ponatinib
increased the CV risk through induction of a pro-
thrombotic state12.
The role of lipoproteins as key initiating events in
atherogenesis is becoming increasingly evident7. Small
ApoB-containing lipoproteins can deposit within the
arterial wall, causing a complex inflammatory process
leading to lipid accumulation and formation of an
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atheromatic plaques It is an established fact that increased
plasma concentrations of cholesterol-rich ApoB-contain-
ing lipoproteins are strongly associated to atherosclerotic
CV disease and that lowering plasma LDL concentrations
reduces CV events in humans13. We found that patients
with triglycerides plasma levels >200mg/dL before start-
ing treatment with ponatinib and with cholesterol plasma
levels >200 mg/dL and LDL > 70mg/dL after 3 months
from the start of ponatinib showed a significantly higher
incidence of AOEs (Fig. 1). The rate of AOEs was similar
considering at 3 months patients with a LDL threshold
above 55 mg/dL. Moreover, we confirmed the predictive
role of the modified SCORE risk system recently pro-
posed8. The recent 2019 ESC/EAS guidelines for the
management of dyslipidemia have highlighted the
importance of lipid modifications to reduce the risk of CV
events8. The authors recommend intervention strategies
to keep the cholesterol and triglycerides values under
200mg/dL and a therapeutic regimen that achieves a
≥50% LDL reduction from baseline and a target of LDL
lower value of <70 mg/dL in high-risk patients and of
<55 mg/dL in very-high patients. In our study, only 27% of
Table 1 Characteristics of patients and cardiovascular profile of 116 CML patients treated with ponatinib.
N (%) N (%)
Sex CVD risk factors
Male 67 (58) Hypertension 26 (22)
Female 49 (42) Dyslipidemia 41 (35)
Age at diagnosis, mean years (range) 49 (23–81) Obesity (BMI > 24.5) 17 (15)
Median follow-up, mean years (range) 3.5 (1–5) Severe renal insufficiency 1 (1)
Leukocyte ×103/µL, mean value (range) 132 (7–515) Diabetes 13 (11)
Hemoglobin g/dL, mean value (range) 12.3 (5–18) Score ≤ 5%a 84 (72)
Platelet ×103/µL, mean value (range) 383 (110–998) Score > 5% 32 (28)
Splenomegaly 68 (59) CVD at baseline
Sokal score Positive anamnesis for CVD 23 (20)
Low 28 (24) Myocardial infarction/angina 7 (6)
Intermediate 59 (51) Arrhythmia 6 (5)
High 29 (25) Other cardiac diseaseb 9 (8)
Line of treatment Peripheral arterial disease 1 (1)
Second line 42 (36) Stroke 1 (1)
Third line 47 (41) Peripheral venous disease 0 (0)
Fourth line 27 (23) CV events following ponatinib
Reason of switch Hypertension 15 (13)
Inefficacy 95 (82) Myocardial infarction/angina 6 (5)
Intolerance 21 (18) Peripheral arterial diseasec 7 (6)
Ponatinib dose at baseline Stroke 3 (3)
15 mg 18 (16) Primary prophylaxis 19 (16)
30 mg 56 (48) Secondary prophylaxis 6 (5)
45 mg 42 (36) Patient treated with statin/fibrate 10 (9)
Ponatinib dose at AOEs in 16 pts Atorvastatin 6 (5)
15 mg 5 (31) Pravastatin 2 (2)
30 mg 6 (38) Lovastatin 1 (1)
45 mg 5 (31) Gemfibrozil 1 (1)
CVD cardiovascular disease, AOEs arterial occlusive events, TKIs tyrosine kinase inhibitors.
aThe SCORE is based on the following risk factors: age, gender, smoking, systolic blood pressure and total cholesterol.
bValvulopathy, restrictive cardiomyopathy, hypertensive cardiomyopathy.
cPAOD, atheromatic carotid disease.
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patients belonged to the SCORE high and very-high risk
group, but treatment with ponatinib could be considered
“per se” a treatment potentially aggravated by athero-
thrombotic and CV complications that require a careful
selection of patients. For this reason we suggest to con-
sider patients aged ≥60 years or all patients with CVD,
dyslipidemia, diabetes, or other CV risk factors before
starting ponatinib, as “CV high risk” patients. These
patients should be carefully investigated and monitored
before and during ponatinib treatment and should
maintain LDL values <70mg/dL (Supplementary Table).
Elevated plasma triglycerides values have been associated
with an increased risk of atherothrombotic CV events. It
has been suggested that the causal effect is determined by
the circulating concentrations of ApoB-containing lipo-
proteins rather than by the triglyceride content14. ApoB
analysis is now recommended for risk assessment, parti-
cularly in people with high triglycerides, diabetes, obesity,
or metabolic syndrome8.
In order to reduce the risk of CV, in addition to change
in lifestyle, a lipid-lowering therapy is recommended. In
our real-life cohort of patients, at CML diagnosis 22% of
Fig. 1 Arterial occlusive events (AOEs) in CML patients according to lipids levels. a AOEs in 82 CML patients according to cholesterol plasma
level >200 mg/dL and LDL > 70mg/dL after 3 months since starting ponatinib. b AOEs in 94 CML patients according to triglycerides plasma level
>200mg/dL before starting ponatinib. LDL low-density lipoprotein, Chol cholesterol.
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them at diagnosis suffered from dyslipidemia that raised
to 35% at the start of ponatinib treatment. Only 9% were
assuming statins or fibrate, clearly indicating an under
estimation of the clinical importance of elevated plasma
lipids as a risk factor for CV events.
During treatment with ponatinib in CV low-
intermediate risk patients, lipid values should be
maintained within the normal range and specific life-
style interventions on dietary habits and physical
activity should be recommended. In patients at high risk
of CV events, a lipid lowering statin-based therapy
aimed at achieving LDL values <70 mg/dL should be
suggested (Supplementary Table). If the goal is not
reached with the maximum dose of statins, combina-
tions with ezetimibe can be considered. In patients
witnessing adverse events with statins, LDL lowering
can be attempted with a different dose scheduling, such
as every other day or twice weekly, with atorvastatin or
rosuvastatin15.
Overall, personalized strategies to minimize the risk of
AOEs should be thoroughly investigated in CML patients
undergoing treatment with ponatinib; this could be par-
ticularly relevant for elderly patients with multiple
comorbidities. These strategies include TKI interruption
in patients with a stable MR4, since treatment-free
remission (TFR) is now an emerging treatment goal for
CML patients and several TFR predictive factors have
been proposed16,17.
Despite the retrospective nature of the study, our find-
ings emphasize that CML patients should be carefully
investigated for their lipid profile at the start of ponatinib
and during treatment in order to implement personalized
prevention strategies based on a careful evaluation of the
patient’s CV risk. Data on the efficacy of measures aimed
at lowering LDL values <70mg/dL in order to reduce
AOEs need to be confirmed in larger cohorts of patients
and in prospective randomized trials.
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